目錄:MedChemExpress LLC>>生化試劑>> Ensitrelvir | MCE
CAS | 2647530-73-0 | 純度 | 99.48% |
---|---|---|---|
分子量 | 531.88 | 分子式 | C??H??ClF?N?O? |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 10 mg |
貨號 | HY-143216 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)。
CAS No. : 2647530-73-0
產(chǎn)品活性:Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM).
研究領(lǐng)域:Anti-infection
作用靶點:SARS-CoV | Virus Protease
In Vitro: In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants. EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively.
In Vivo: Ensitrelvir dose-dependently inhibits intrapulmonary replication of SARS-CoV-2 in mice.
相關(guān)產(chǎn)品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Anti-Infection Compound Library | Clinical Compound Library | Antiviral Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Heterocyclic Compound Library | SRPIN340 | Antimicrobial agent-10 | SARS-CoV-2-IN-23 | Aminothiazole | 3CPLro-IN-1 | SP inhibitor 1 | rel-Zotatifin | Antioxidant agent-9 | Regdanvimab | Silymarin | NHC-triphosphate tetraammonium | Grazoprevir potassium salt | Atazanavir | Genkwanin | FWM-4 | L-Lysine-15N2 (hydrochloride) | Aspirin-d4 | Amantadine-d6 | Ketotifen fumarate | (-)-α-Pinene | SARS-CoV-2-IN-27 | 2'-Deoxy-2'-fluoro-l-uridine | LabMol-319 | MMT5-14 | Tipranavir | Amantadine | Sotrovimab | 4E2RCat | HCVcc-IN-1 | Antiviral agent 5
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。